DOCSLIB.ORG

Kv-Ada-Jdbc210013 1..3

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Kv-Ada-Jdbc210013 1..3 Diabetes Care Volume 44, June 2021 e1 Performance of the Insulin-Only Luz E. Castellanos,1 Courtney A. Balliro,1 Jordan S. Sherwood,1 Rabab Jafri,1 iLet Bionic Pancreas and the Mallory A. Hillard,1 Evelyn Greaux,1 Rajendranath Selagamsetty,2 Hui Zheng,3 Bihormonal iLet Using Firas H. El-Khatib,2 Edward R. Damiano,2,4 and Dasiglucagon in Adults With Type Steven J. Russell1 1 Diabetes in a Home-Use Setting Diabetes Care 2021;44:e1–e3 | https://doi.org/10.2337/DC20-1086 Reductions in blood glucose levels in with insulin lispro (Eli Lilly) or aspart (Table 1). The mean CGM glucose and people with diabetes are often (Novo Nordisk), the bihormonal iLet for time in range (70–180 mg/dL) were 149 achieved at the expense of increased 7 days with dasiglucagon (4 mg/mL) ±13mg/dLand72±8%,respectively,in hypoglycemia. A novel approach is to and insulin lispro or aspart, or both, us- the insulin-only period, and 139 ± 11 automatically deliver microdose gluca- ing the same glucose target (110 mg/ mg/dL and 79 ± 9%, respectively, in the gon when automation of insulin deliv- dL), in random order. There were no re- bihormonal period. The mean daily car- ery alone is not sufficient to prevent strictions on diet or exercise. The prima- bohydrates consumed to prevent or hypoglycemia. The approach requires a ry outcomes were prespecified iLet treat hypoglycemia were 16 ± 13 g and bihormonal device and a stable form of operational thresholds. The key second- 18 ± 21 g in the insulin-only and bihor- glucagon or glucagon analog. The iLet ary outcome was the median time with monal periods, respectively. bionic pancreas (Beta Bionics, Inc.) is a CGM glucose <54 mg/dL on days 2–7 The mean total daily dose (TDD) of purpose-built, fully integrated device (after one day of adaptation). dasiglucagon was 0.35 mg/day. All that receives a signal from a continuous All participants completed the study. subjects used one prefilled dasigluca- glucose monitor (CGM) and contains Participants were 21–74 years old and gon cartridge for the entire 7-day pe- autonomous, lifelong learning, mathe- had initial HbA1c levels of 5.7–10.6%. riod. The average daily nausea scores matical dosing algorithms, which are The iLet achieved a CGM capture rate of on a 0–10 visual analog scale were initialized only with the patient’sbody $80% during the insulin-only (90.7%) 0.07 ± 0.12 cm and 0.47 ± 0.83 cm in weight (1). We evaluated the function and bihormonal (88.7%) periods (Table the insulin-only and bihormonal peri- and safety of the iLet in both its insulin- 1). Drug dosing was available >95% of ods, respectively. One participant re- e-LETTER only configuration and its bihormonal the time (99.7% and 99.1% for insulin in ported an episode of vomiting during configuration delivering dasiglucagon, a the insulin-only and bihormonal periods, the bihormonal period. – chemically stable glucagon analog (Zea- respectively, and 99.7% for dasigluca- There were five instances of con- OBSERVATION land Pharma), in a home-use study in gon). The ratio of delivered to attempted firmed insulin leakage at the insulin car- adults with type 1 diabetes (T1D). drug volume was 95–105% (100.3% and tridge connector (one in the bihormonal This open-label, random-order, cross- 99.9% for insulin in the insulin-only and and four in the insulin-only period) that over, home-use trial (clinical trial reg. bihormonal periods, respectively, and led to replacement of the insulin car- no. NCT03840278, ClinicalTrials.gov) 102.0% for dasiglucagon). tridge and connector. In participants was the first human study to test the The median percentage of time with who had confirmed leaks, the insulin bihormonal iLet configuration and the CGM glucose <54 mg/dL was 0.6% (in- TDD was 1.4–3.3-fold higher (mean TDD first multiday use of dasiglucagon in terquartile range [IQR] 0.2–1.1%) and 1.3 vs. 0.6 units/kg/day) and the mean people with T1D (2). Ten participants 0.2% (IQR 0–0.4%) in the insulin-only CGM glucose was 30–72 mg/dL higher used the insulin-only iLet for 7 days and bihormonal periods, respectively (mean 197 vs. 139 mg/dL) on days with 1Massachusetts General Hospital Diabetes Research Center, Boston, MA 2Beta Bionics, Inc., Concord, MA 3Massachusetts General Hospital Biostatistics Center, Boston, MA 4Department of Biomedical Engineering, Boston University, Boston, MA Corresponding author: Steven J. Russell, [email protected] Received 8 May 2020; and accepted 1 March 2021 Clinical trial reg. no. NCT03840278, clinicaltrials.gov © 2021 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at https://www.diabetesjournals.org/content/license. Diabetes Care Publish Ahead of Print, published online April 27, 2021 e2 Performance of the iLet Using Dasiglucagon Diabetes Care Volume 44, June 2021 Table 1—Summary of results iLet operational performance targets Insulin-only iLet Bihormonal iLet iLet operational outcomes CGM glucose readings captured, % $80 90.7 88.7 Insulin delivery channel availability, % $95 99.7 99.1 Ratio of cumulative delivered to attempted insulin volume, % 95–105 100.3 99.9 Glucagon delivery channel availability, % $95 99.7 Ratio of cumulative delivered to attempted glucagon volume, % 95–105 102.0 CGM glucose outcomes ADA consensus targets (3) Insulin-only iLet Bihormonal iLet Median % of time <54 mg/dL (IQR) <1 0.6 (0.2–1.1) 0.2 (0–0.4) Median % of time <70 mg/dL (IQR) <4 4.0 (2.8–4.8) 2.0 (1.3–3.3) Mean CGM glucose, mg/dL (SD) 149 (13) 139 (11) Mean % of time 70–180 mg/dL (SD) >70 72 (8) 79 (9) Mean % of time >180 mg/dL (SD) <25 24 (8) 18 (8) Mean % of time >250 mg/dL (SD) <5 6 (5) 4 (4) Mean coefficient of variation, % (SD) <36 38 (7) 36 (7) Mean standard deviation, mg/dL (SD) 57 (14) 50 (13) Nonglycemic outcomes Mean daily carbohydrates for prevention or treatment of 16 (13) 18 (21) hypoglycemia, g (SD) Dasiglucagon doses, mg/day (SD) 0.35 (0.13) Insulin doses, unit/kg/day (SD) 0.72 (0.23) 0.60 (0.19) As prespecified, iLet operational outcomes are reported for days 1–7, and CGM glucose outcomes and nonglycemic outcomes are reported for days 2–7. ADA, American Diabetes Association. confirmedleaksthanondaysinthe or occlusions supports the practicality the Board of Directors of Beta Bionics, Inc. same arm without documented leaks. for this liquid formulation in clinical R.S. is an employee in, and holds options to purchase stock in, Beta Bionics, Inc. S.J.R. is There were no occlusions or infusion site use. These results support testing the an inventor on a patent and patents pending reactions. There was no severe hypoglyce- next-generation iLet with dasigluca- on aspects of the bionic pancreas that are as- mia or diabetic ketoacidosis, and there were gon in much larger and longer pivotal signed to Massachusetts General Hospital and no serious or unexpected adverse events. trials. are licensed to Beta Bionics; has received Both iLet configurations met the pre- honoraria and/or travel expenses for lectures fi from Novo Nordisk, Roche, and Ascensia; speci ed operational performance targets. serves on the scientific advisory boards of Un- Acknowledgments. The authors thank the However, leaks occurred at the insulin car- omedical and Companion Medical; has received participants for their time and effort; the dia- tridge connector. This was due to off-cen- consulting fees from Beta Bionics, Novo Nordisk, betes care providers who referred potential Senseonics, and Flexion Therapeutics; has re- ter piercing of the cartridge septum prior participants to the study staff; the Massachu- ceived grant support from Zealand Pharma, to insertion into the iLet that led to leak- setts General Hospital (MGH) Diabetes Re- Novo Nordisk, and Beta Bionics; and has re- search Center study staff, Mary Larkin, age through an enlarged hole in the ceived in-kind support in the form of technical septum after needle insertion. This obser- Camille Staco-Targete, Nancy Kingori, Stepha- nie Dimodica, Khadija Tlaiti, and the Diabetes support and/or donation of materials from Zea- vation led to changes in the cartridge re- Research Center, MGH, for organizational and land Pharma, Ascencia, Senseonics, Adocia, and fl placement procedure and to design logistical support; Michele Sullivan for partici- Tandem Diabetes. No other potential con icts of changes in the next-generation cartridge pating in the conduct of the trial; Camille interest relevant to this article were reported. Powe, Kerry Grennan, and Takara Stanley Author Contributions. L.E.C. and E.G. wrote connector and iLet that will be used in the fi (MGH Pediatric Endocrine Division) for serving the rst draft of the letter. L.E.C., H.Z., and pivotal clinical trial. Despite insulin leakage, on the data safety and monitoring board for S.J.R. interpreted the data. C.A.B., J.S.S., R.J., the mean CGM glucose and time in range the study; and the members of the Partners M.A.H., E.G., R.S., F.H.E.-K., E.R.D., and S.J.R. were similar to those observed in previous Human Research Committee. participated in revision of the letter for impor- tant intellectual content. C.A.B., R.J., M.A.H., trials, likely due to autonomous adaptation Funding. L.E.C.
Load more

Recommended publications
  • Diabetic Ketoacidosis and Hyperosmolar BMJ: First Published As 10.1136/Bmj.L1114 on 29 May 2019
    STATE OF THE ART REVIEW Diabetic ketoacidosis and hyperosmolar BMJ: first published as 10.1136/bmj.l1114 on 29 May 2019. Downloaded from hyperglycemic syndrome: review of acute decompensated diabetes in adult patients Esra Karslioglu French,1 Amy C Donihi,2 Mary T Korytkowski1 1Division of Endocrinology and Metabolism, Department of ABSTRACT Medicine, University of Pittsburgh, Pittsburgh, PA, USA Diabetic ketoacidosis and hyperosmolar hyperglycemic syndrome (HHS) are life threatening 2University of Pittsburgh School of complications that occur in patients with diabetes. In addition to timely identification of the Pharmacy, Pittsburgh, PA, USA Correspondence to: M Korytkowski precipitating cause, the first step in acute management of these disorders includes aggressive [email protected] administration of intravenous fluids with appropriate replacement of electrolytes (primarily Cite this as: BMJ 2019;365:l1114 doi: 10.1136/bmj.l1114 potassium). In patients with diabetic ketoacidosis, this is always followed by administration Series explanation: State of the of insulin, usually via an intravenous insulin infusion that is continued until resolution of Art Reviews are commissioned on the basis of their relevance to ketonemia, but potentially via the subcutaneous route in mild cases. Careful monitoring academics and specialists in the US and internationally. For this reason by experienced physicians is needed during treatment for diabetic ketoacidosis and HHS. they are written predominantly by Common pitfalls in management include premature termination of intravenous insulin US authors therapy and insufficient timing or dosing of subcutaneous insulin before discontinuation of intravenous insulin. This review covers recommendations for acute management of diabetic ketoacidosis and HHS, the complications associated with these disorders, and methods for http://www.bmj.com/ preventing recurrence.
    [Show full text]
  • Glossary of Common Diabetes Terms
    Glossary of Common Diabetes Terms A1C: a test that reveals exactly how well your blood sugar (glucose) has been controlled over the previous three months Beta cells: cells found in the pancreas that make insulin Blood glucose: also known as blood sugar, glucose comes from food and is then carried through the blood to deliver energy to cells Blood glucose meter: a small medical device used to check blood glucose levels Blood glucose monitoring: the simple blood test used to check the amount of glucose in the blood; a tiny drop of blood, taken by pricking a finger, is placed on a test strip and inserted in the meter for reading Diabetes: the shortened name for diabetes mellitus, the condition in which the pancreas doesn’t produce enough insulin or your body is unable to use insulin to move glucose into cells of the body Diabetic retinopathy: the eye disease that occurs in someone with diabetes when the small blood vessels of the retina become swollen and leak liquid into the retina, blurring vision; it can sometimes lead to blindness Gestational diabetes: the diabetes some women develop during pregnancy; it typically subsides after the baby is delivered, but many women who have had gestational diabetes may develop type 2 diabetes later in life Glucagon: the hormone that is injected into a person with diabetes to raise their blood glucose level when it’s very low (hypoglycemia) Glucose: blood sugar that gives energy to cells Hyperglycemia: also known as high blood glucose, this condition occurs when your blood glucose level is too high;
    [Show full text]
  • Acute Renal Failure in Patients with Type 1 Diabetes Mellitus G
    Postgrad Med J: first published as 10.1136/pgmj.70.821.192 on 1 March 1994. Downloaded from Postgrad Med J (1994) 70, 192- 194 C) The Fellowship of Postgraduate Medicine, 1994 Acute renal failure in patients with type 1 diabetes mellitus G. Woodrow, A.M. Brownjohn and J.H. Turney Renal Unit, Leeds General Infirmary, Great George Street, Leeds LSJ 3EX, UK Summary: Acute renal failure (ARF) is a serious condition which still carries a mortality of around 50%. People with diabetes may be at increased risk of developing ARF, either as a complication of diabetic ketoacidosis or hyperosmolar coma, increased incidence of cardiovascular disease, or due to increased susceptibility ofthe kidney to adverse effects in the presence ofunderlying diabetic renal disease. During the period 1956-1992, 1,661 cases of ARF have been treated at Leeds General Infirmary. Of these, we have identified 26 patients also having type 1 diabetes. ARF due to diabetic ketoacidosis is surprisingly uncommon (14 cases out of 23 patients whose notes were reviewed). All cases of ARF complicating ketoacidosis in the last decade have been associated with particularly severe illness requiring intensive care unit support, rather than otherwise 'uncomplicated' ketoacidosis. We discuss the conditions that may result in ARF in patients with diabetes and the particular difficulties that may be encountered in management. Introduction People with diabetes may be at increased risk of Results developing acute renal failure (ARF). Acute pre- copyright. renal failure may occur as a result ofthe severe fluid Of 23 patients with type 1 diabetes complicated by depletion associated with diabetic ketoacidosis and ARF, diabetic ketoacidosis was the main underly- non-ketotic hyperosmolar coma.
    [Show full text]
  • End-Stage Renal Disease Increases Rates of Adverse Glucose Events When Treating Diabetic Ketoacidosis Or Hyperosmolar Hyperglycemic State Caitlin M
    Clinical Diabetes Papers in Press, published online May 3, 2017 End-Stage Renal Disease Increases Rates of Adverse Glucose Events When Treating Diabetic Ketoacidosis or Hyperosmolar Hyperglycemic State Caitlin M. Schaapveld-Davis,1 Ana L. Negrete,1,2 Joanna Q. Hudson,1–3 Jagannath Saikumar,3 Christopher K. Finch,1,2 Mehmet Kocak,4 Pan Hu,4 and Megan A. Van Berkel,1,2 FEATURE ARTICLE FEATURE ■ IN BRIEF Treatment guidelines for diabetic emergencies are well described in patients with normal to moderately impaired kidney function. However, management of patients with end-stage renal disease (ESRD) is an ongoing challenge. This article describes a retrospective study comparing the rates of adverse glucose events (defined as hypoglycemia or a decrease in glucose >200 mg/dL/hour) between patients with ESRD and those with normal kidney function who were admitted with diabetic ketoacidosis (DKA) or hyperosmolar hyperglycemic state (HHS). These results indicate that current treatment approaches to DKA or HHS in patients with ESRD are suboptimal and require further evaluation. anagement strategies for dia- den, characterized by an exchange of betic ketoacidosis (DKA) and the intracellular potassium ion pool Mhyperosmolar hyperglycemic for the newly increased extracellular state (HHS) are well established in hydrogen ion concentration (1–3). patients with normal kidney function. In contrast, patients with ESRD and Therapy typically includes aggressive DKA or HHS are routinely observed fluid resuscitation, electrolyte replace- to have hyperkalemia resulting from ment, insulin administration, and a combination of transcellular shifts treatment of the precipitating cause and a lack of renal clearance, thus (if identified). However, treatment eliminating the need for electrolyte strategies for these key principles replacement (4).
    [Show full text]
  • Diabetic Ketoacidosis: Evaluation and Treatment DYANNE P
    Diabetic Ketoacidosis: Evaluation and Treatment DYANNE P. WESTERBERG, DO, Cooper Medical School of Rowan University, Camden, New Jersey Diabetic ketoacidosis is characterized by a serum glucose level greater than 250 mg per dL, a pH less than 7.3, a serum bicarbonate level less than 18 mEq per L, an elevated serum ketone level, and dehydration. Insulin deficiency is the main precipitating factor. Diabetic ketoacidosis can occur in persons of all ages, with 14 percent of cases occurring in persons older than 70 years, 23 percent in persons 51 to 70 years of age, 27 percent in persons 30 to 50 years of age, and 36 percent in persons younger than 30 years. The case fatality rate is 1 to 5 percent. About one-third of all cases are in persons without a history of diabetes mellitus. Common symptoms include polyuria with polydipsia (98 percent), weight loss (81 percent), fatigue (62 percent), dyspnea (57 percent), vomiting (46 percent), preceding febrile illness (40 percent), abdominal pain (32 percent), and polyphagia (23 percent). Measurement of A1C, blood urea nitro- gen, creatinine, serum glucose, electrolytes, pH, and serum ketones; complete blood count; urinalysis; electrocar- diography; and calculation of anion gap and osmolar gap can differentiate diabetic ketoacidosis from hyperosmolar hyperglycemic state, gastroenteritis, starvation ketosis, and other metabolic syndromes, and can assist in diagnosing comorbid conditions. Appropriate treatment includes administering intravenous fluids and insulin, and monitoring glucose and electrolyte levels. Cerebral edema is a rare but severe complication that occurs predominantly in chil- dren. Physicians should recognize the signs of diabetic ketoacidosis for prompt diagnosis, and identify early symp- toms to prevent it.
    [Show full text]
  • Diabetic Ketoacidosis Diabetic Ketoacidosis (DKA) Is a Serious Problem That Can Happen in People with Diabetes
    Diabetic Ketoacidosis Diabetic ketoacidosis (DKA) is a serious problem that can happen in people with diabetes. DKA should be treated as a medical emergency. This is because it can lead to coma or death. If you have the symptoms of DKA, get medical help right away. DKA happens more often in people with type 1 diabetes. But it can happen in people with type 2 diabetes. It can also happen in women with diabetes during pregnancy (gestational diabetes). DKA happens when insulin levels are too low. Without enough insulin, sugar (glucose) can’t get to the cells of your body. The glucose stays in the blood. The liver then puts out even more glucose into the blood. This causes high blood glucose (hyperglycemia). Without glucose, your body breaks down stored fat for energy. When this happens, acids called ketones are released into the blood. This is called ketosis. High levels of ketones (ketoacidosis) can be harmful to you. Hyperglycemia and ketoacidosis can also cause serious problems in the blood and your body, such as: • Low levels of potassium (hypokalemia) and phosphate • Damage to kidneys or other organs • Coma What causes diabetic ketoacidosis? In people with diabetes, DKA is most often caused by too little insulin in the body. It is also caused by: • Poor management of diabetes • Infections such as a urinary tract infection or pneumonia • Serious health problems, such as a heart attack • Reactions to certain prescribed medicines including SGLT2 inhibitors for treating type 2 diabetes • Reactions to illegal drugs including cocaine • Disruption of insulin delivery from an insulin pump Symptoms of diabetic ketoacidosis DKA most often happens slowly over time.
    [Show full text]
  • Serum 1, 5-Anhydroglucitol to Glycated Albumin Ratio Can Help
    Hindawi Journal of Diabetes Research Volume 2020, Article ID 1243630, 8 pages https://doi.org/10.1155/2020/1243630 Research Article Serum 1,5-Anhydroglucitol to Glycated Albumin Ratio Can Help Early Distinguish Fulminant Type 1 Diabetes Mellitus from Newly Onset Type 1A Diabetes Mellitus Lingwen Ying , Xiaojing Ma , Yun Shen, Jingyi Lu , Wei Lu, Wei Zhu, Yufei Wang , Yuqian Bao , and Jian Zhou Department of Endocrinology and Metabolism, Shanghai Clinical Center for Diabetes, Shanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai 200233, China Correspondence should be addressed to Jian Zhou; [email protected] Received 9 December 2019; Accepted 5 March 2020; Published 21 March 2020 Academic Editor: Jonathan M. Peterson Copyright © 2020 Lingwen Ying et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Background. Fulminant type 1 diabetes mellitus (FT1DM) onsets abruptly and usually occurs within 1 week after the onset of hyperglycemic symptoms. Glycated albumin (GA) and 1,5-anhydroglucitol (1,5-AG) are indicators that reflect short-term glucose levels. This study was aimed at investigating whether the 1,5-AG/GA index (AGI) is a suitable indicator for early FT1DM fi ð Þ : % identi cation. Methods. A total of 226 subjects were enrolled, all with glycated hemoglobin A1c HbA1c <87 . FT1DM was diagnosed based on the 2012 Japan Diabetes Society criteria. Results. The AGI level was 0.54 (0.17–1.36) in the whole group.
    [Show full text]
  • Dapagliflozin- Induced Severe Ketoacidosis Requiring Hemodialysis Ossama Maadarani*, Zouheir Bitar and Rashed Alhamdan
    Maadarani et al. Clin Med Rev Case Rep 2016, 3:150 Volume 3 | Issue 12 Clinical Medical Reviews ISSN: 2378-3656 and Case Reports Case Report: Open Access Dapagliflozin- Induced Severe Ketoacidosis Requiring Hemodialysis Ossama Maadarani*, Zouheir Bitar and Rashed Alhamdan Internal medical department, Ahmadi hospital, Kuwait *Corresponding author: Ossama Maadarani, Cardiologist, Internal medical department, Ahmadi hospital, Kuwait oil company, PO Box 46468, Fahahil 64015, Kuwait, Tel: 0096-566986503, E-mail: [email protected] emergency department with vague symptoms of general weakness, Abstract malaise, nausea, and shortness of breath of one week duration. He The availability of novel classes of medication for the treatment denies vomiting, fever, or diarrhea. His regular medications included of type 2 Diabetes mellitus (type 2 DM) provides doctors with metformin 1000 mg twice daily, glimepiride 4 mg once daily and options to choose individualized treatments based on patient and insulin glargine 20 units at night. Because of uncontrolled blood agent characteristics beyond metformin therapy, as per current sugar as evidenced by high hemoglobin A1C (HbA1c) levels of 10.9%, guidelines. Independent of impaired beta-cell function and insulin he was started on dapagliflozin 5 mg once daily one month before resistance, sodium glucose cotransporter type 2 (SGLT2) inhibitors represent a different treatment strategy for reducing plasma recent presentation to the emergency room (ER). He did not stop his glucose levels and glycosylated hemoglobin concentrations insulin glargine (20 units once at night) but he stopped glimepiride by increasing urinary glucose excretion through reduced renal by himself to reduce number of tablets that he is taking. He denied glucose reabsorption.
    [Show full text]
  • Diabetic Ketoacidosis
    Diabetic ketoacidosis Diabetic Ketoacidosis Dr. Christiane Stengel Dipl. ECVIM-CA (IM) FTÄ für Kleintiere High blood glucose with the presence of ketones in the urine and bloodstream, often caused by having/giving too little insulin or during illness. Dr. Christiane Stengel Diabetic ketoacidosis v Diabetes mellitus not diagnosed so far (common) v Or „derailed“ Diabetes (possible) & a “triggering condition” lead to increased „counter- regulatory“ hormones: o Glucagon ↑ o Cortisol ↑ o Adrenalin ↑ o GH ↑ v Low insulin and high glucagon increased glucagon:insulin-ratio medpets.de v Bacterial infections v Endocrine disease o Urinary tract o Hypercortisolism o Pneumonia o Hypothyroidism o Pyometra /prostatitis o Hyperthyroidism o Pyoderma o Acromegaly v Inflammatory v Physiological condition endocrine change o Pancreatitis o Dioestrus v Iatrogenic v Miscellaneous o Steroid administration o Chronic kidney disease o Neoplasia Dr. Christiane Stengel Diabetic ketoacidosis v Vomiting, lethargy, anorexia, weakness, (PU/PD), triggering effect signs v Severe dehydration (hypovolaemic shock) o Glukosuria osmotic diuresis o Ketonuria osmotic diuresis o Fluid loss from vomiting o Decreased fluid intake from anorexia and lethargy A. Kussmaul v Tachycardia, change in pulse quality, colour and capillary refill time v Increased breathing effort (often with normal frequency) due to metabolic acidosis (Kussmaul breathing) , ketone smell v Haematology v Biochemistry profile ± ketones in plasma v Urinalysis and urine culture v Blood gas analysis v ± abdominal
    [Show full text]
  • Clinical Usefulness of the Measurement of Serum Fructosamine in Childhood Diabetes Mellitus
    Original article http://dx.doi.org/10.6065/apem.2015.20.1.21 Ann Pediatr Endocrinol Metab 2015;20:21-26 Clinical usefulness of the measurement of serum fructosamine in childhood diabetes mellitus Dong Soo Kang, MD1, Purpose: Glycosylated hemoglobin (HbA1c) is often used as an indicator of glucose Jiyun Park, MD1, control. It usually reflects the average glucose levels over two to three months, and Jae Kyung Kim, PhD2, is correlated with the development of long-term diabetic complications. However, Jeesuk Yu, MD, PhD1 it can vary in cases of hemoglobinopathy or an altered red blood cell lifespan. The serum fructosamine levels reflect the mean glucose levels over two to three weeks. 1 This study was designed to determine the clinical usefulness of the combined Departments of Pediatrics and 2Laboratory Medicine, Dankook measurement of serum fructosamine and HbA1c in the management of childhood University Hospital, Dankook diabetes mellitus and the correlation between them. University College of Medicine, Methods: Clinical data on 74 Korean children and adolescents with diabetes Cheonan, Korea mellitus who were under management at the Department of Pediatrics of Dankook University Hospital were evaluated. Their fructosamine and HbA1c levels were reviewed based on clinical information, and analyzed using IBM SPSS Statistics ver. 21. Results: Their HbA1c levels showed a strong correlation with their fructosamine levels (r=0.868, P<0.001). The fructosamine level was useful for the prompt evaluation of the recent therapeutic efficacy after the change in therapeutic modality. It was also profitable in determining the initial therapeutics and for the estimation of the onset of the disease, such as fulminant diabetes.
    [Show full text]
  • Serum Fructosamine Concentration in Uncontrolled Hyperthyroid Diabetic Cats Is Within the Population Reference Interval
    veterinary sciences Article Serum Fructosamine Concentration in Uncontrolled Hyperthyroid Diabetic Cats Is within the Population Reference Interval Arnon Gal 1,*, Brie Trusiano 2, Adrienne F. French 3, Nicolas Lopez-Villalobos 1 and Amy L. MacNeill 2 1 Institute of Veterinary, Animals and Biomedical Sciences, Massey University, Tennent Drive, Palmerston North 4442, New Zealand; [email protected] 2 Microbiology, Immunology & Pathology Dept., Colorado State University, 1682 Campus Delivery, Fort Collins, CO 80523, USA; [email protected] (B.T.); [email protected] (A.L.M.) 3 New Zealand Veterinary Pathology/IDEXX, Tennent Drive, Palmerston North 4442, New Zealand; [email protected] * Correspondence: [email protected]; Tel.: +64-6-951-8241 Academic Editor: Jacquie Rand Received: 16 October 2016; Accepted: 12 March 2017; Published: 15 March 2017 Abstract: Diabetes mellitus is a common endocrinopathy of cats that is characterized by persistent fasting hyperglycemia. However, stress induces substantial hyperglycemia in cats that poses a challenge to the veterinarian who may wrongly interpret the high serum concentration of blood glucose as evidence of diabetes mellitus. Fructosamine is a glycated serum protein that serves as an index of glycemic control in cats and is useful because it is not affected by stress hyperglycemia. However, factors such as body weight, hypoproteinemia, and increased serum thyroid hormone concentration can alter fructosamine concentration. The goal of this retrospective study was to compare the fructosamine concentrations in diabetic and nondiabetic cats with and without uncontrolled hyperthyroidism. A secondary goal was to determine the effect of sex, age, different populations of cats, and diabetes on the variability of fructosamine.
    [Show full text]
  • Diabetes – Glossary of Terms
    DIABETES – GLOSSARY OF TERMS Diabetes is a common condition, which most people have some understanding of, but when you listen to people talk about it, you may feel as if it has language of its own – full of words and terms that you have never heard of. It does not matter if you are newly diagnosed or have been diagnosed for some time, it always helps to refresh your understanding of the everyday words used in diabetes, as terms can change. Rather than assuming you know the meanings of the words used, listed here alphabetically, are the most common ones you will hear when you are discussing your diabetes with your care team. A. Annual review is an essential check of your health that everyone with diabetes should have once a year. It includes various blood tests and physical examinations and also offers an opportunity to chat with your diabetes healthcare team about your diabetes and any issues relating to it. Autoimmune is where something goes wrong with the immune defence and the cells of your own body are attacked. This is seen in Type 1 diabetes, as the insulin producing cells of the pancreas are destroyed by a process in the body known as “autoimmunity” in which the body’s cells attack each other, leading to loss of insulin production. A1c See HbA1c B. Beta cells are cells in the islets of your pancreas that produce insulin. Blood glucose level is the amount of glucose in your blood. Blood glucose meters are electronic machines (biosensors) that your diabetes care team and you can use to test your current blood glucose level.
    [Show full text]